CAC Score (Coronary Calcium) Interpretation by Decade of Life

What Is a CAC Score and How Is It Measured?

A CAC score quantifies calcified atherosclerotic plaque in the coronary arteries using a non-contrast CT scan scored by the Agatston method. The result is a single number measured in Agatston units (AU). Zero means no detectable calcified plaque; scores above 400 indicate heavy burden. The scan takes about 10 minutes, requires no contrast dye, and delivers roughly 1 millisievert of radiation.

The Agatston Method

Each calcified lesion is scored by multiplying its area (mm²) by a density factor (1-4) based on peak Hounsfield units. Scores from all lesions are summed. Scores are reproducible across CT platforms when acquisition protocols follow Society of Cardiovascular Computed Tomography standards.

Why Raw Score Alone Is Insufficient

A 55-year-old woman with a CAC of 75 sits at roughly the 90th percentile for her age and sex. A 70-year-old man with the same score of 75 sits below the 50th percentile. Identical Agatston numbers carry radically different prognostic weight depending on the demographic context. This is why the 2019 AHA/ACC Cholesterol Guidelines explicitly recommend using age- and sex-specific percentile data when applying CAC to clinical decisions. [1]

MESA as the Reference Cohort

The Multi-Ethnic Study of Atherosclerosis (MESA, N=6,814) remains the most-cited source of CAC percentile norms across White, Black, Hispanic, and Chinese-American adults aged 45-84. [2] MESA data are freely accessible through a web-based calculator that returns the percentile rank for any age, sex, race, and raw CAC value.

CAC Score Interpretation in Your 40s (Ages 40-49)

Any detectable calcium in a 40-something is a significant finding. The median CAC in this decade is 0 for both men and women in MESA. [2] A score above 0 places most 40-year-olds above the 75th percentile and should prompt at minimum a reconsideration of statin therapy even when the pooled cohort equation (PCE) 10-year risk is below 7.5%.

What CAC = 0 Means at This Age

A zero score at 40-49 years is genuinely reassuring. The MESA and Framingham Offspring data show that CAC = 0 is associated with a 10-year MACE rate below 1% in this age group. [3] Clinicians sometimes call this a "negative risk certificate" for the next 5-7 years, though lifestyle risk factors still warrant attention.

When Any Calcium Is Too Much

The ACC/AHA guidelines state that a CAC score above the 75th percentile for age and sex is sufficient to reclassify an intermediate-risk patient to high risk and initiate statin therapy. [1] For a 45-year-old man, the 75th percentile is approximately 32 AU. For a 45-year-old woman, it is approximately 1 AU, meaning any detectable calcium crosses that threshold. The clinical implication is that women in their 40s who show any calcification deserve prompt risk escalation.

Statin Decision Thresholds in the 40s

According to the 2019 ACC/AHA guidelines, CAC scoring is particularly useful for patients in the "risk discussion zone" where the 10-year PCE falls between 5% and 20%. [1] In the 40s, a CAC of 1-99 AU combined with a borderline PCE risk (5-7.5%) is sufficient for a Class IIa recommendation to start moderate-intensity statin therapy.

CAC Score Interpretation in Your 50s (Ages 50-59)

The 50s are when calcification becomes common even in otherwise healthy adults. Median CAC in MESA for 50-59-year-old men is approximately 36 AU; for women in the same decade, it is approximately 0 AU. [2] A score of 100 in a 55-year-old man sits near the 60th percentile; the same score in a 55-year-old woman sits above the 90th percentile.

The Gender Gap in This Decade

Women's coronary calcium accumulation lags behind men's by roughly 10 years on average, a pattern attributed partly to estrogen's anti-atherogenic effects before menopause. [4] The MESA investigators found that postmenopausal women who underwent early surgical menopause had CAC scores approximately 19 AU higher than women who experienced natural menopause at the expected age. [4] Hormone status therefore informs how aggressively a given CAC score should be interpreted in a 50-something woman.

CAC 1-99 AU: The "Mild" Category

Scores in this range indicate at least one calcified plaque but limited total burden. The MESA data show that adults with CAC 1-99 have a 10-year MACE risk approximately 7.7% higher than those with CAC = 0, even after adjustment for traditional risk factors. [3] This magnitude of reclassification is clinically meaningful and generally tips borderline-risk patients toward statin initiation.

CAC 100-299 AU: Moderate Burden

At 50-59 years, a score of 100-299 AU places a man near the 70th-80th percentile and a woman well above the 90th percentile. [2] Both the AHA/ACC and the AACE lipid guidelines treat this range as an indication for high-intensity statin therapy when LDL-C is elevated. The AACE 2022 Dyslipidemia Guidelines list CAC 100-299 as a "very high risk" feature in intermediate-risk patients. [5]

CAC Score Interpretation in Your 60s (Ages 60-69)

Median CAC rises sharply in the sixth decade. In MESA, the median for 60-69-year-old men is approximately 103 AU; for women it is approximately 32 AU. [2] A score of 200 in a 65-year-old man sits near the 60th percentile, but the same score in a 65-year-old woman sits near the 85th percentile. Raw numbers must always be paired with percentile context.

Absolute Score Versus Percentile Rank

The Rotterdam Heart Study (N=2,013 participants aged 55+) demonstrated that CAC percentile rank predicted coronary events independently of absolute score. [6] Participants at or above the 75th percentile for age and sex had a hazard ratio for coronary heart disease of approximately 3.1 (95% CI 2.0-4.7) compared with those below the median. [6]

Reclassification Impact in the 60s

At this age, PCE 10-year risk scores frequently exceed 10%, placing many patients in the "statin-indicated" category by default. CAC scoring then shifts from initiation decisions to intensity decisions: does a score above 300 justify high-intensity rather than moderate-intensity therapy? The ACC/AHA guidelines answer yes for patients with LDL-C between 70 and 189 mg/dL and CAC above 100 AU. [1]

CAC and Aspirin Decisions in the 60s

The 2022 USPSTF guideline recommends against initiating aspirin for primary prevention in adults aged 60 and older. [7] CAC does not override this recommendation. However, some longevity-medicine practitioners note that a very high CAC (above 400 AU) in a 62-year-old with otherwise controlled risk factors opens a shared-decision-making conversation about aspirin that should involve explicit bleeding risk quantification.

CAC Score Interpretation in Your 70s and Beyond (Ages 70+)

Coronary calcification becomes nearly universal in this decade. MESA data show median CAC of approximately 180 AU in men aged 70-84 and approximately 65 AU in women. [2] The diagnostic and prognostic calculus shifts: the question is less about whether plaque exists and more about how much plaque above average is present.

When CAC = 0 Is Remarkable at 70+

A zero score in a 75-year-old is genuinely unusual and carries significant protective weight. The CAC Consortium study (N=66,636) found that adults over 70 with CAC = 0 had 10-year MACE rates of approximately 2.5%, substantially lower than the 12-15% predicted by pooled cohort equations for most 70-year-olds. [8] Clinicians should note this disparity when making statin or aspirin decisions.

Very High Scores: CAC Above 1,000 AU

Scores above 1,000 AU occur in roughly 5-10% of men aged 70-79. [2] The CAC Consortium data link scores in this range to a 10-year MACE hazard ratio of approximately 9.8 compared with CAC = 0. [8] Maximum-intensity statin therapy, blood-pressure control to below 130/80 mmHg, and referral for stress testing are all warranted at this level.

Treatment Ceiling Effects

Several geriatric cardiology societies note that aggressive lipid-lowering in patients over 80 carries its own complexity, including statin myopathy risk and questions about net benefit in limited life expectancy. The 2023 American Geriatrics Society Beers Criteria do not list statins as potentially inappropriate in older adults, but they recommend individualizing therapy based on functional status and patient preference. [9]

Percentile Tables: MESA Reference Data by Age and Sex

The table below summarizes approximate MESA percentile cutoffs for CAC score by age decade. These values are rounded from the published MESA data. [2]

| Age Range | Sex | 25th Pctile | 50th Pctile | 75th Pctile | 90th Pctile | |---|---|---|---|---|---| | 45-49 | Male | 0 | 0 | 32 | 120 | | 45-49 | Female | 0 | 0 | 1 | 25 | | 50-54 | Male | 0 | 1 | 88 | 230 | | 50-54 | Female | 0 | 0 | 11 | 70 | | 55-59 | Male | 0 | 36 | 163 | 398 | | 55-59 | Female | 0 | 0 | 52 | 154 | | 60-64 | Male | 0 | 103 | 320 | 625 | | 60-64 | Female | 0 | 32 | 157 | 351 | | 65-69 | Male | 0 | 180 | 467 | 882 | | 65-69 | Female | 0 | 65 | 263 | 559 | | 70-76 | Male | 14 | 251 | 634 | 1,104 | | 70-76 | Female | 0 | 95 | 383 | 756 |

All values in Agatston units. Race-specific data available at the MESA CAC calculator (mesa-nhlbi.org).

Progression Rate: How Fast Should CAC Grow?

CAC scores are not static. Annual progression of roughly 15-25% of baseline score is common in adults with established plaque. [10] A patient who had a CAC of 80 AU at age 52 and returns at 57 with a score of 300 AU has shown accelerated progression that carries additional prognostic weight beyond the absolute score.

Statin Effect on Progression

Statin therapy reduces the rate of new plaque formation but paradoxically may increase the density (and therefore Agatston score) of existing plaques through calcification of previously non-calcified plaque. [11] The MESA Progression study found that statin users showed higher annual CAC progression in absolute Agatston units than non-users, yet had lower MACE rates, suggesting that dense, calcified plaque is more stable than the lipid-rich, non-calcified variety. [11] This finding means a rising CAC score does not necessarily indicate worsening prognosis in a patient already on statin therapy.

Repeat Scanning Intervals

The Society of Cardiovascular Computed Tomography recommends considering a repeat scan in 3-5 years for patients with an initial CAC of 1-99 AU who remain in the intermediate-risk PCE category. [12] For CAC = 0 at baseline, a repeat in 5 years is reasonable in patients who develop new risk factors. Repeat scanning before 3 years rarely changes management and adds unnecessary radiation exposure.

CAC Score and Non-Calcified Plaque: The Missing Burden

A CAC score measures only calcified plaque. Coronary CT angiography (CCTA) studies consistently show that non-calcified plaque, particularly low-attenuation (lipid-rich) plaque, is the substrate most likely to rupture and cause acute MI. [13] This creates a clinical framework HealthRX clinicians use when counseling patients:

The Three-Tier CAC Interpretation Framework

1. CAC = 0, low PCE risk: Reassure, recheck in 5 years, optimize lifestyle.
2. CAC = 0, high PCE risk (above 15%) or strong family history: Consider CCTA to rule out non-calcified plaque before deferring statin therapy.
3. CAC above 0: Manage by absolute score, age-sex percentile, and PCE integration per ACC/AHA 2019 guidelines.

The PROMISE trial (N=10,003) found that CCTA detected obstructive coronary artery disease in 9.7% of stable chest-pain patients who had a CAC of 0. [14] That trial reinforced the principle that a zero CAC score does not eliminate non-calcified plaque as a clinical concern in symptomatic patients, even if it is powerfully reassuring in asymptomatic screening.

Guideline Recommendations: When to Order a CAC Scan

The 2019 AHA/ACC Cholesterol Guidelines give CAC scoring a Class IIa recommendation (benefit outweighs risk, reasonable to perform) in adults aged 40-75 with LDL-C between 70 and 189 mg/dL who fall in the "risk discussion zone" (PCE 7.5-20%) and in whom the decision to start statin therapy remains uncertain after full risk discussion. [1]

Direct Guideline Language

The 2019 ACC/AHA guidelines state: "If a risk decision is uncertain, measurement of CAC is reasonable for adults 40-75 years of age without diabetes mellitus and with LDL-C 70-189 mg/dL, at a 10-year atherosclerotic CVD risk of 5-20%, and for adults 40-75 years of age with diabetes mellitus." [1] This language places CAC as a tie-breaker, not a first-line universal screen.

AACE Endorsement

The American Association of Clinical Endocrinology 2022 Guidelines for Dyslipidemia include CAC as a risk-enhancing factor that may reclassify patients from intermediate to high risk, justifying statin intensification or initiation. [5] The AACE guidelines specifically note CAC scores above 100 AU as independently sufficient for very-high-risk classification in borderline patients.

Patients Who Should Not Have CAC Scans

CAC scanning is not indicated in adults already established as high risk (prior MI, stroke, or 10-year PCE above 20%), because the result will not change the management decision. It is also not recommended as a universal population screen, as noted in the 2018 USPSTF evidence review on cardiovascular screening. [15]

Integration With Other Biomarkers

CAC does not operate in isolation. Combining CAC with high-sensitivity CRP (hs-CRP) and ankle-brachial index (ABI) improves the C-statistic for 10-year MACE prediction from approximately 0.76 (PCE alone) to approximately 0.81. [16] The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with LDL-C below 130 mg/dL but elevated hs-CRP above 2 mg/L, many of whom would also have had detectable CAC. [17]

Lipoprotein(a) and CAC

Lipoprotein(a) (Lp(a)) is a genetically determined lipid particle that accelerates calcification and plaque formation independent of LDL-C. Adults with Lp(a) above 100 nmol/L and a CAC above 100 AU may have substantially higher MACE risk than their PCE score suggests. [18] Both the ESC 2021 Cardiovascular Prevention Guidelines and the ACC/AHA 2019 guidelines list elevated Lp(a) as a risk-enhancing factor that informs CAC interpretation. [1]

ApoB and Particle Number

ApoB concentration, which reflects the total number of atherogenic lipoprotein particles, correlates more tightly with plaque burden than LDL-C in several studies. [19] Patients with discordantly high ApoB but apparently normal LDL-C (a pattern seen in metabolic syndrome) may show higher-than-expected CAC for their PCE risk tier. Ordering ApoB alongside CAC can resolve this discordance and clarify statin intensity decisions.